Compare
Foundayo vs. Wegovy

Foundayo (orforglipron) is an oral glucagon-like peptide-1 (GLP-1) receptor agonist. It's approved for weight loss in certain adults. This medication is meant to be used together with a reduced-calorie diet and exercise. Foundayo (orforglipron) comes as tablets and is taken by mouth once a day with or without food. The dose is slowly raised over several weeks. Common side effects include nausea, constipation, and diarrhea.

• Weight loss and long-term weight management in adults who are considered obese or overweight with at least one weight-related condition

• Nausea (26-35%)
• Constipation (20-27%)
• Diarrhea (21-25%)
• Vomiting (13-24%)
• Indigestion (12-16%)
• Stomach pain (13-14%)
• Headache (8-9%)
• Bloating (7-9%)
• Feeling tired (6-9%)
• Belching (6-8%)
• Gastroesophageal reflux disease (GERD; 6-7%)
• Having a lot of gas (5-6%)
• Hair loss (4-5%)

• Possible risk of thyroid cancer
• Severe stomach side effects
• Kidney damage
• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems
• Low blood sugar
• Allergic reactions
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Lung problems during general anesthesia or deep sedation

Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It comes in prefilled pens you use to inject the medication under the skin once a week. Wegovy (semaglutide) also comes as tablets that are swallowed once a day. This medication is approved for weight loss in some people. It can help lower the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease. The pens are also approved for certain adults with a liver problem called metabolic dysfunction-associated steatohepatitis (MASH). The medication works best when taken with a lower-calorie diet and regular exercise. Side effects include nausea, diarrhea, and stomach pain.

Injectable pens:

• Weight loss and long-term weight management in:

  • People ages 12 years and older who are considered obese
  • Adults considered overweight with at least one weight-related condition (e.g., high blood pressure, Type 2 diabetes, high cholesterol)

• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver scarring, but not cirrhosis

Tablets:

• Weight loss and long-term weight management in adults who are considered obese or overweight with at least one weight-related condition
• Lowering the risk of heart attack, stroke, and death due to heart problems in adults with a larger body size and heart disease

• Nausea (44%)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Stomach pain (20%)
• Headache (14%)
• Tiredness (11%)

• Possible risk for thyroid cancer
• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems
• Low blood sugar
• Kidney damage
• Allergic reactions
• Eye problems in people with Type 2 diabetes (diabetic retinopathy)
• Faster heart rate
• Lung problems during general anesthesia or deep sedation